Dense Deposit Disease
📧 Sign up to get email alerts when something new happens for Dense Deposit Disease.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-03-30Clinical Trial Update: Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721 [Phase 2]
Omeros' Phase 2 safety study of OMS721 in immunoglobulin A nephropathy, lupus nephritis, membranous nephropathy, and C3 glomerulopathy inclu…
-
CLINICAL_TRIALS approval · 2025-11-06Clinical Trial Update: C3G/Primary IC-MPGN EAP
Apellis' pegylated C3 inhibitor pegcetacoplan has gained marketing approval for C3 glomerulopathy and immune complex–mediated MPGN as part o…
-
CLINICAL_TRIALS trial_result · 2025-08-06Clinical Trial Update: Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis [Phase 3]
Phase 3 trial evaluating pegcetacoplan for C3 glomerulopathy and immune-complex membranoproliferative glomerulonephritis has completed with …
-
CLINICAL_TRIALS research · 2025-06-22Clinical Trial Update: Evaluation of a Renin Inhibitor, Aliskiren, Compared to Enalapril, in C3 Glomerulopathy [Phase 2]
Phase 2 trial evaluating aliskiren (a renin inhibitor) versus enalapril in C3 glomerulopathy and related glomerulonephritis, currently recru…
-
CLINICAL_TRIALS trial_result · 2025-02-13Clinical Trial Update: Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies [Phase 2]
Phase II trial of APL-2 in glomerulopathies completed; results have been posted.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-02-07Clinical Trial Update: Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN [Phase 2]
Phase 2 trial assessing pegcetacoplan for post-transplant recurrence of C3 glomerulopathy and immune complex-mediated MPGN has completed wit…
-
CLINICAL_TRIALS trial_result · 2022-08-11Clinical Trial Update: A Proof of Concept Study for a 12 Month Treatment in Patients With C3G or IC-MPGN Treated With ACH-0144471 [Phase 2]
Phase 2 proof-of-concept trial for a 12-month treatment in C3 glomerulopathy-related conditions (C3 Glomerulonephritis/IC-MPGN) with ACH-014…
-
CLINICAL_TRIALS trial_result · 2021-11-04Clinical Trial Update: A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G) [Phase 2]
Phase 2 proof-of-concept trial of danicopan for six months in participants with C3 glomerulopathy has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2021-07-13Clinical Trial Update: A Proof-of-Mechanism Study to Determine the Effect of Danicopan on C3 Levels in Participants With C3G or IC-MPGN [Phase 2]
Phase 2 trial assessing danicopan effects on C3 levels in participants with C3 glomerulopathy or IC-MPGN; the study is completed with result…
-
CLINICAL_TRIALS trial_result · 2019-02-19Clinical Trial Update: Eculizumab Therapy for Dense Deposit Disease and C3 Nephropathy [Phase 1]
A Phase 1 trial evaluating eculizumab for dense deposit disease and C3 nephropathy has completed, with results posted in 2019.
-
CLINICAL_TRIALS withdrawal · 2016-10-27Clinical Trial Update: TP10 Use in Patients With C3 Glomerulopathy (C3G) [Phase 1]
A Phase 1 trial of TP10 in patients with C3 glomerulopathy (Dense Deposit Disease) has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2015-06-11Clinical Trial Update: Sulodexide Treatment in Patients With Dense Deposit Disease [Phase 1]
A Phase 1 trial of sulodexide for Dense Deposit Disease has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2014-03-07Clinical Trial Update: Clinical Trial of CDX-1135 in Pediatric and Adult Patients With Dense Deposit Disease [Phase 1]
A Phase 1 trial of CDX-1135 in pediatric and adult patients with Dense Deposit Disease and related glomerulonephritides was terminated.